治療代謝病症之抗-AP2抗體及抗原結合劑农业专利-农业专业知识服务系统

发明人:: 哈特米斯里基　格克翰Ｓ,ROBERTS, ELISABETH HELEN,罗伯特斯　伊丽莎白　海伦,羅伯特斯　伊麗莎白　海倫,MOORE, ADRIAN RICHARD,穆尔　安德里　理查德,穆爾　安德里　理查德,DOYLE, CARL BRENDAN,德理　卡罗　布兰登,德理　卡羅　布蘭登,ADAMS, RALPH,艾当斯　罗夫,艾當斯　羅夫,赫夫　凯琳　杰尼　马德理,赫,哈特米斯里基格克翰S,罗伯特斯伊丽莎白海伦,羅伯特斯伊麗莎白海倫,穆尔安德里理查德,穆爾安德里理查德,德理卡罗布兰登,德理卡羅布蘭登,艾当斯罗夫,艾當斯羅夫,赫夫凯琳杰尼马德理

摘要：: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.本發明係關於改良之抗-aP2抗體及抗原結合劑以及其組合物，該等抗體靶向脂質伴護蛋白aP2/FABP4(稱為「aP2」)，尤其用於治療諸如糖尿病、肥胖、心血管疾病、脂肪肝及/或癌症之病症。在一個態樣中，揭示改良之aP2介導之病症治療，其中使用低結合親和力之aP2單株抗體，靶向血清aP2且中和或調節aP2之生物活性，提供較低空腹血糖含量、改善全身性葡萄糖代謝、增加全身性胰島素敏感性、降低脂肪量、降低肝臟脂肪變性、減少心血管疾病及/或降低出現心血管疾病之風險。